Journal of Clinical Densitometry
Volume 12, Issue 2 , Pages 135-157 , April 2009

2008 Santa Fe Bone Symposium: Update on Osteoporosis

  • E. Michael Lewiecki

      Affiliations

    • New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, USA
    • Corresponding Author InformationAddress correspondence to: E. Michael Lewiecki, MD, FACP, FACE, New Mexico Clinical Research & Osteoporosis Center, 300 Oak St. NE, Albuquerque, NM 87106.
    • ,
  • Sanford Baim

      Affiliations

    • Colorado Center for Bone Research, Lakewood, CO, USA
    • ,
  • John P. Bilezikian

      Affiliations

    • Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA
    • ,
  • Richard Eastell

      Affiliations

    • Academic Unit of Bone Metabolism, University of Sheffield, Sheffield, UK
    • ,
  • Meryl S. LeBoff

      Affiliations

    • Harvard Medical School, Boston, MA, USA
    • ,
  • Paul D. Miller

      Affiliations

    • Colorado Center for Bone Research, Lakewood, CO, USA

Received 9 December 2008 ,Revised 26 February 2009 ,Accepted 26 February 2009.

References 

  1. Lewiecki EM, Bilezikian JP, Cooper C, et al. Proceedings of the Eighth Annual Santa Fe Bone Symposium, August 3–4, 2007. J Clin Densitom. 2008;11(2):313–324
  2. Lewiecki EM. Proceedings of the Santa Fe Bone Symposium 2006. Women's Health. 2006;2(6):825–828
  3. US Department of Health and Human Services . Bone health and osteoporosis: a report of the surgeon general. Rockville, MD: US Department of Health and Human Services, Office of the Surgeon General; 2004;
  4. National Osteoporosis Foundation . Clinician's guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation; 2008;
  5. Cole ZA, Dennison EM, Cooper C. Osteoporosis epidemiology update. Curr Rheumatol Rep. 2008;10(2):92–96
  6. Tosteson AN, Melton LJ, Dawson-Hughes B, et al. Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int. 2008;19(4):437–447
  7. WHO Scientific Group on the assessment of osteoporosis at primary health care level. University of Sheffield, UK: World Health Organization; 2004;Printed by the University of Sheffield
  8. Hans D, Downs RW, Duboeuf F, et al. Skeletal sites for osteoporosis diagnosis: the 2005 ISCD Official Positions. J Clin Densitom. 2006;9(1):15–21
  9. Hans DB, Shepherd JA, Schwartz EN, et al. Peripheral dual-energy X-ray absorptiometry in the management of osteoporosis: the 2007 ISCD Official Positions. J Clin Densitom. 2008;11(1):188–206
  10. Khosla S, Melton LJ. Osteopenia. Clinical practice N Engl J Med. 2007;356(22):2293–2300
  11. Siris ES, Brenneman SK, Miller PD, et al. Predictive value of low BMD for 1-year fracture outcomes is similar for postmenopausal women ages 50-64 and 65 and older: results from the National Osteoporosis Risk Assessment (NORA). J Bone Miner Res. 2004;19(8):1215–1220
  12. Pasco JA, Seeman E, Henry MJ, et al. The population burden of fractures originates in women with osteopenia, not osteoporosis. Osteoporos Int. 2006;17(9):1404–1409
  13. Sornay-Rendu E, Munoz F, Garnero P, et al. Identification of osteopenic women at high risk of fracture: the OFELY study. J Bone Miner Res. 2005;20(10):1813–1819
  14. Kanis JA on behalf of the World Health Organization Scientific Group. 2007 Assessment of osteoporosis at the primary health-care level. Technical Report. University of Sheffield, UK: World Health Organization Collaborating Centre for Metabolic Bone Diseases; 2007;Printed by the University of Sheffield
  15. Sanders KM, Nicholson GC, Watts JJ, et al. Half the burden of fragility fractures in the community occur in women without osteoporosis. When is fracture prevention cost-effective?. Bone. 2006;38(5):694–700
  16. World Health Organization . FRAX WHO fracture risk assessment tool. World Health Organization; 2008;Available at: http://www.shef.ac.uk/FRAX/. Accessed March 23, 2009
  17. Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19(4):385–397
  18. Kanis JA, Oden A, Johnell O, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int. 2007;18(8):1033–1046
  19. Kanis JA, Black D, Cooper C, et al. A new approach to the development of assessment guidelines for osteoporosis. Osteoporos Int. 2002;13(7):527–536
  20. Kanis JA, Johnell O, De Laet C, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone. 2004;35(2):375–382
  21. Kanis JA, Borgstrom F, De Laet C, et al. Assessment of fracture risk. Osteoporos Int. 2005;16(6):581–589
  22. Kanis JA, Johnell O, Oden A, et al. Smoking and fracture risk: a meta-analysis. Osteoporos Int. 2005;16(2):155–162
  23. Kanis JA, Johansson H, Johnell O, et al. Alcohol intake as a risk factor for fracture. Osteoporos Int. 2005;16(7):737–742
  24. Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res. 2004;19(6):893–899
  25. Dargent-Molina P, Favier F, Grandjean H, et al. Fall-related factors and risk of hip fracture: the EPIDOS prospective study. Lancet. 1996;348(9021):145–149
  26. Jarvinen TL, Sievanen H, Khan KM, et al. Shifting the focus in fracture prevention from osteoporosis to falls. BMJ. 2008;336(7636):124–126
  27. Bayly J, Masud T. Preventing falls: not at the expense of osteoporosis care. BMJ. 2008;336(7640):343
  28. Dawson-Hughes B, Tosteson AN, Melton LJ, et al. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int. 2008;19(4):449–458
  29. Binkley N, Bilezikian JP, Kendler DL, et al. Official Positions of the International society for clinical densitometry and executive summary of the 2005 position development conference. J Clin Densitom. 2006;9(1):4–14
  30. Lenchik L, Leib ES, Hamdy RC, et al. Executive summary International society for clinical densitometry position development conference Denver, Colorado July 20–22, 2001. J Clin Densitom. 2002;5(Suppl):S1–S3
  31. Leib ES, Lewiecki EM, Binkley N, Hamdy RC. Official Positions of the International society for clinical densitometry. J Clin Densitom. 2004;7(1):1–6
  32. Baim S, Binkley N, Bilezikian JP, et al. Official Positions of the International society for clinical densitometry and executive summary of the 2007 ISCD position development conference. J Clin Densitom. 2008;11(1):75–91
  33. Baim S, Leonard MB, Bianchi ML, et al. Official Positions of the International society for clinical densitometry and executive summary of the 2007 ISCD pediatric position development conference. J Clin Densitom. 2008;11(1):6–21
  34. Cochrane reviews handbook. Vol. 4.1.5. Oxford, UK: The Cochrane Collaboration; 2002;
  35. Fitch K, Bernstein SJ, Aguilar B, et al. The RAND/UCLA appropriateness method user's manual. Santa Monica, CA: The RAND Corporation; 2001;
  36. Krieg MA, Barkmann R, Gonnelli S, et al. Quantitative ultrasound in the management of osteoporosis: the 2007 ISCD Official Positions. J Clin Densitom. 2008;11(1):163–187
  37. Engelke K, Adams JE, Armbrecht G, et al. Clinical use of quantitative computed tomography and peripheral quantitative computed tomography in the management of osteoporosis in adults: the 2007 ISCD Official Positions. J Clin Densitom. 2008;11(1):123–162
  38. Cummings SR, McClung MR, Christiansen C, et al. A phase III study of the effects of denosumab on vertebral, nonvertebral, and hip fracture in women with osteoporosis: results from the FREEDOM trial. J Bone Miner Res. 2008;23(Suppl 1):S80
  39. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434–1441
  40. Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med. 2007;357(9):905–916
  41. Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003;349(13):1207–1215
  42. Finkelstein JS, Hayes A, Hunzelman JL, et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med. 2003;349(13):1216–1226
  43. Deal C, Omizo M, Schwartz EN, et al. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res. 2005;20(11):1905–1911
  44. Miller PD, Delmas PD, Lindsay R, et al. Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab. 2008;93(10):3785–3793
  45. Black DM, Bilezikian JP, Ensrud KE, et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med. 2005;353(6):555–565
  46. Cosman F, Nieves J, Zion M, et al. Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med. 2005;353(6):566–575
  47. Eastell R, Hannon RA. Biomarkers of bone health and osteoporosis risk. Proc Nutr Soc. 2008;67(2):157–162
  48. Valimaki MJ, Tahtela R, Jones JD, et al. Bone resorption in healthy and osteoporotic postmenopausal women: comparison markers for serum carboxy-terminal telopeptide of type I collagen and urinary pyridinium cross-links. Eur J Endocrinol. 1994;131(3):258–262
  49. Kushida K, Takahashi M, Kawana K, Inoue T. Comparison of markers for bone formation and resorption in premenopausal and postmenopausal subjects, and osteoporosis patients. J Clin Endocrinol Metab. 1995;80(8):2447–2450
  50. Eastell R, Robins SP, Colwell T, et al. Evaluation of bone turnover in type I osteoporosis using biochemical markers specific for both bone formation and bone resorption. Osteoporos Int. 1993;3(5):255–260
  51. Schneider DL, Barrett-Connor EL. Urinary N-telopeptide levels discriminate normal, osteopenic, and osteoporotic bone mineral density. Arch Intern Med. 1997;157:1241–1245
  52. Meier C, Meinhardt U, Greenfield JR, et al. Serum cathepsin K concentrations reflect osteoclastic activity in women with postmenopausal osteoporosis and patients with Paget's disease. Clin Lab. 2006;52(1–2):1–10
  53. Rogers A, Hannon RA, Eastell R. Biochemical markers as predictors of rates of bone loss after menopause. J Bone Miner Res. 2000;15(7):1398–1404
  54. Mole PA, Walkinshaw MH, Robins SP, Paterson CR. Can urinary pyridinium crosslinks and urinary oestrogens predict bone mass and rate of bone loss after the menopause. Eur J Clin Invest. 1992;22:767–771
  55. Uebelhart D, Schlemmer A, Johansen JS, et al. Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links. J Clin Endocrinol Metab. 1991;72(2):367–373
  56. Cosman F, Nieves J, Wilkinson C, et al. Bone density change and biochemical indices of skeletal turnover. Calcif Tissue Int. 1996;58:236–243
  57. Dresner-Pollak R, Parker R, Poku M, et al. Biochemical markers of bone turnover reflect femoral bone loss in elderly women. Calcif Tissue Int. 1996;59:328–333
  58. Bauer DC, Sklarin PM, Stone KL, et al. Biochemical markers of bone turnover and prediction of hip bone loss in older women: the study of osteoporotic fractures. J Bone Miner Res. 1999;14(8):1404–1410
  59. Garnero P, Sornay-Rendu E, Duboeuf F, Delmas PD. Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: the OFELY study. J Bone Miner Res. 1999;14(9):1614–1621
  60. Hannon RA, Eastell R. Biochemical markers of bone turnover and fracture prediction. J Br Menopause Soc. 2003;9(1):10–15
  61. Gerdhem P, Ivaska KK, Alatalo SL, et al. Biochemical markers of bone metabolism and prediction of fracture in elderly women. J Bone Miner Res. 2004;19(3):386–393
  62. Garnero P, Hausherr E, Chapuy M-C, et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS prospective study. J Bone Miner Res. 1996;11:1531–1538
  63. Melton LJ, Khosla S, Atkinson EJ, et al. Relationship of bone turnover to bone density and fractures. J Bone Miner Res. 1997;12:1083–1091
  64. Garnero P, Cloos P, Sornay-Rendu E, et al. Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: the OFELY prospective study. J Bone Miner Res. 2002;17(5):826–833
  65. Sarkar S, Reginster JY, Crans GG, et al. Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res. 2004;19(3):394–401
  66. Garnero P, Dargent-Molina P, Hans D, et al. Do markers of bone resorption add to bone mineral density and ultrasonographic heel measurement for the prediction of hip fracture in elderly women? The EPIDOS prospective study. Osteoporos Int. 1998;8(6):563–569
  67. Greenspan SL, Resnick NM, Parker RA. Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial. J Clin Endocrinol Metab. 2005;90(5):2762–2767
  68. Greenspan SL, Rosen HN, Parker RA. Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women. J Clin Endocrinol Metab. 2000;85(10):3537–3540
  69. Ravn P, Thompson DE, Ross PD, Christiansen C. Biochemical markers for prediction of 4-year response in bone mass during bisphosphonate treatment for prevention of postmenopausal osteoporosis. Bone. 2003;33(1):150–158
  70. Chen P, Satterwhite JH, Licata AA, et al. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res. 2005;20(6):962–970
  71. Bauer DC, Garnero P, Bilezikian JP, et al. Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2006;91(4):1370–1375
  72. Eastell R, Barton I, Hannon RA, et al. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res. 2003;18:1051–1056
  73. Clowes JA, Peel NF, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab. 2004;89(3):1117–1123
  74. Cummings SR, Browner WS, Bauer D, et al. Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group. N Engl J Med. 1998;339(11):733–738
  75. Chapurlat RD, Garnero P, Bréart G, et al. Serum estradiol and sex hormone-binding globulin and the risk of hip fracture in elderly women: the EPIDOS study. J Bone Miner Res. 2000;15(9):1835–1841
  76. Vestergaard P, Rejnmark L, Mosekilde L. Effect of tamoxifen and aromatase inhibitors on the risk of fractures in women with breast cancer. Calcif Tissue Int. 2008;82(5):334–340
  77. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005;365(9453):60–62
  78. Forbes JF, Cuzick J, Buzdar A, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9(1):45–53
  79. Eastell R, Adams JE, Coleman RE, et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol. 2008;26(7):1051–1057
  80. Eastell R, Hannon RA, Cuzick J, et al. Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res. 2006;21(8):1215–1223
  81. Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353(26):2747–2757
  82. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349(19):1793–1802
  83. Harper-Wynne C, Ross G, Sacks N, et al. Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention. Cancer Epidemiol Biomarkers Prev. 2002;11(7):614–621
  84. Coates AS, Keshaviah A, Thurlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol. 2007;25(5):486–492
  85. Perez EA, Josse RG, Pritchard KI, et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol. 2006;24(22):3629–3635
  86. Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 2007;369(9561):559–570
  87. Geisler J, Lonning PE, Krag LE, et al. Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study. Eur J Cancer. 2006;42(17):2968–2975
  88. Brufsky A, Bundred N, Coleman R, et al. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist. 2008;13(5):503–514
  89. Bundred NJ, Campbell ID, Davidson N, et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. Cancer. 2008;112(5):1001–1010
  90. Ellis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol. 2008;26(30):4875–4882
  91. Reid DM, Doughty J, Eastell R, et al. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev. 2008;34(Suppl 1):S3–S18
  92. Cooper C, Campion G, Melton LJ. Hip fractures in the elderly: a world-wide projection. Osteoporos Int. 1992;2(6):285–289
  93. Colon-Emeric CS, Biggs DP, Schenck AP, Lyles KW. Risk factors for hip fracture in skilled nursing facilities: who should be evaluated?. Osteoporos Int. 2003;14(6):484–489
  94. Schroder HM, Petersen KK, Erlandsen M. Occurrence and incidence of the second hip fracture. Clin Orthop Relat Res. 1993;289:166–169
  95. Wolinsky FD, Fitzgerald JF. Subsequent hip fracture among older adults. Am J Public Health. 1994;84(8):1316–1318
  96. Gullberg G, Johnell O, Kanis JA. World-wide projections for hip fracture. Osteoporos Int. 1997;7:407–413
  97. Melton LJ, Eddy DM, Johnston CC. Screening for osteoporosis. Ann Intern Med. 1990;112:516–528
  98. Foley KA, Foster SA, Meadows ES, et al. Assessment of the clinical management of fragility fractures and implications for the new HEDIS osteoporosis measure. Med Care. 2007;45(9):902–906
  99. LeBoff MS, Kohlmeier L, Hurwitz S, et al. Occult vitamin D deficiency in postmenopausal US women with acute hip fracture. JAMA. 1999;281(16):1505–1511
  100. LeBoff MS, Hawkes WG, Glowacki J, et al. Vitamin D-deficiency and post-fracture changes in lower extremity function and falls in women with hip fractures. Osteoporos Int. 2008;19(9):1283–1290
  101. Pieper CF, Colon-Emeric C, Caminis J, et al. Distribution and correlates of serum 25-hydroxyvitamin D levels in a sample of patients with hip fracture. Am J Geriatr Pharmacother. 2007;5(4):335–340
  102. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357(18):1799–1809
  103. Cauley JA, LaCroix AZ, Wu L, et al. Serum 25-hydroxyvitamin D concentrations and risk for hip fractures. Ann Intern Med. 2008;149(4):242–250
  104. Eriksen EF, Lyles KW, Colon-Emeric CS, et al. Antifracture Efficacy and Reduction of Mortality in Relation to Timing of First Dose of Zoledronic Acid After Hip Fracture. J Bone Miner Res. Epub. 2009;
  105. Streeten EA, Mohamed A, Gandhi A, et al. The inpatient consultation approach to osteoporosis treatment in patients with a fracture. Is automatic consultation needed?. J Bone Joint Surg Am. 2006;88(9):1968–1974
  106. Edwards BJ, Langman CB, Bunta AD, et al. Secondary contributors to bone loss in osteoporosis related hip fractures. Osteoporos Int. 2008;19(7):991–999
  107. Solomon DH, Morris C, Cheng H, et al. Medication use patterns for osteoporosis: an assessment of guidelines, treatment rates, and quality improvement interventions. Mayo Clin Proc. 2005;80(2):194–202
  108. Majumdar SR, Beaupre LA, Harley CH, et al. Use of a case manager to improve osteoporosis treatment after hip fracture: results of a randomized controlled trial. Arch Intern Med. 2007;167(19):2110–2115
  109. Harrington JT, Barash HL, Day S, Lease J. Redesigning the care of fragility fracture patients to improve osteoporosis management: a health care improvement project. Arthritis Rheum. 2005;53(2):198–204
  110. Tosi LL, Gliklich R, Kannan K, Koval KJ. The American Orthopaedic Association's “own the bone” initiative to prevent secondary fractures. J Bone Joint Surg Am. 2008;90(1):163–173
  111. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006;81(8):1013–1022
  112. Lewiecki EM. Medications don't work if patients don't take them. South Med J. 2007;100(12):1190–1191
  113. Miller PD, Bonnick SL, Rosen C. Guidelines for the clinical utilization of bone mass measurement in the adult population. Society for Clinical Densitometry. Calcif Tissue Int. 1995;57(4):251–252
  114. Miller PD. Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction. Curr Osteoporos Rep. 2005;3(3):103–110
  115. Bonnick SL, Shulman L. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both?. Am J Med. 2006;119(4 Suppl 1):S25–S31
  116. Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab. 2000;85(1):231–236
  117. Miller PD, Hochberg MC, Wehren LE, et al. How useful are measures of BMD and bone turnover?. Curr Med Res Opin. 2005;21(4):545–554
  118. Hochberg MC, Greenspan S, Wasnich RD, et al. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab. 2002;87(4):1586–1592
  119. Bonnick SL, Johnston CC, Kleerekoper M, et al. Importance of precision in bone density measurements. J Clin Densitom. 2001;4(2):105–110
  120. Bonnick SL. Bone densitometry in clinical practice- application and interpretation. 2nd ed.. Totowa, NJ: Humana Press; 2004;
  121. Shepherd JA, Lu Y, Wilson K, et al. Cross-calibration and minimum precision standards for dual-energy X-ray absorptiometry: The 2005 ISCD Official Positions. J Clin Densitom. 2006;9(1):31–36
  122. Lewiecki EM. Nonresponders to osteoporosis therapy. J Clin Densitom. 2003;6(4):307–314
  123. Delmas PD, Eastell R, Garnero P, et al. The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int. 2000;11(Suppl 6):S2–S17
  124. Miller PD, Baran DT, Bilezikian JP, et al. Practical clinical application of biochemical markers of bone turnover: consensus of an expert panel. J Clin Densitom. 1999;2(3):323–342
  125. Srivastava AK, Vliet EL, Lewiecki EM, et al. Clinical use of serum and urine bone markers in the management of osteoporosis. Curr Med Res Opin. 2005;21(7):1015–1026
  126. Vokes T, Bachman D, Baim S, et al. Vertebral fracture assessment: the 2005 ISCD Official Positions. J Clin Densitom. 2006;9(1):37–46
  127. Lewiecki EM, Watts NB. Assessing response to osteoporosis therapy. Osteoporos Int. 2008;19(10):1363–1368
  128. Miller PD. Anti-resorptives in the management of osteoporosis. Best Pract Res Clin Endocrinol Metab. 2008;22(5):849–868
  129. Miller PD, Delmas PD, Huss H, et al. Increases in hip and spine bone mineral density are predictive for anti-fracture efficacy. J Bone Miner Res, in press.
  130. Garnero P, Delmas PD. Contribution of bone mineral density and bone turnover markers to the estimation of risk of osteoporotic fracture in postmenopausal women. J Musculoskelet Neuronal Interact. 2004;4(1):50–63
  131. Lewiecki EM, Laster AJ. Clinical applications of vertebral fracture assessment by dual-energy X-ray absorptiometry. J Clin Endocrinol Metab. 2006;91(11):4215–4222
  132. Genant HK, Wu CY, van KC, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993;8(9):1137–1148
  133. Schousboe JT, Ensrud KE, Nyman JA, et al. Cost-effectiveness of vertebral fracture assessment to detect prevalent vertebral deformity and select postmenopausal women with a femoral neck T-score>-2.5 for alendronate therapy: a modeling study. J Clin Densitom. 2006;9(2):133–143
  134. Fleisch H, Russell RG, Francis MD. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science. 1969;165:1262–1264
  135. Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med. 1990;323:73–79
  136. Miller PD. Bisphosphonates: pharmacology and use in the treatment of osteoporosis. 3rd ed.. San Diego, CA: Elsevier Academic Press; 2007;1725–1736
  137. Delmas PD, Adami S, Strugala C, et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum. 2006;54(6):1838–1846
  138. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809–1822
  139. Miller PD, McClung MR, Macovei L, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res. 2005;20(8):1315–1322
  140. Harris ST, Blumentals WA, Miller PD. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr Med Res Opin. 2008;24(1):237–245
  141. Cranney A, Wells GA, Yetisir E, et al. Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int. 2008;20(2):291–297
  142. Boniva [package insert]. 2008 Roche Pharmaceuticals, Nutley, NJ.
  143. Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med. 2002;346:653–661
  144. Reid IR, Miller P, Lyles K, et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med. 2005;353(9):898–908
  145. Heckbert SR, Li G, Cummings SR, et al. Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med. 2008;168(8):826–831
  146. Sorensen HT, Christensen S, Mehnert F, et al. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ. 2008;336(7648):813–816
  147. U.S. Food and Drug Administration . Early communication of an ongoing safety review. U.S. Food and Drug Administration; 2007;Available at: http://www.fda.gov/cder/drug/early_comm/biophosphonates.htm. Accessed Decenber 1, 2008.
  148. U.S. Food and Drug Administration . Update of safety review follow-up to the October 1, 2007. Early communication about the ongoing safety review of bisphosphonates. U.S. Food and Drug Administration; 2008;Available at: http://www.fda.gov/cder/drug/early_comm/biophosphosphonates_update_200811.htm. Accessed February 24, 2008
  149. Lewiecki EM, Miller PD. Renal safety of intravenous bisphosphonates in the treatment of osteoporosis. Expert Opin Drug Saf. 2007;6(6):663–672
  150. Boonen S, Sellmeyer DE, Lippuner K, et al. Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int. 2008;74(5):641–648
  151. Miller P, Leigh C, Ward P. Renal tolerability of intravenous ibandronate allows administration by short injection. Ann Rheum Dis. 2006;65(Suppl 2):422
  152. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004;62(5):527–534
  153. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Ress. 2007;22(10):1479–1489
  154. Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med. 2008;358(12):1304–1306
  155. Neviaser AS, Lane JM, Lenart BA, et al. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma. 2008;22(5):346–350

PII: S1094-6950(09)00015-8

doi: 10.1016/j.jocd.2009.02.002

Journal of Clinical Densitometry
Volume 12, Issue 2 , Pages 135-157 , April 2009

Article Tools

* Image Usage & Resolution